New pill targets rare cancer gene in last-resort patients

NCT ID NCT04962867

Recruiting now Disease control Sponsor: National Cancer Center, Japan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called E7090 in people with advanced or returning solid tumors that have a specific change in the FGFR gene. About 75 participants will receive the drug to see if it can shrink tumors and control the disease. The goal is to offer a new option for patients who have run out of standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Apert syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR RECURRENT SOLID TUMORS FGFR GENE ALTERATIONS

Contacts and locations

Locations

Hokkaido University Hospital
RECRUITING

Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan
Kanagawa Cancer Center
RECRUITING

Yokohama, Kanagawa, 241-8515, Japan
Kyoto University Hospital
RECRUITING

Sakyo-ku, Kyoto, 606-8507, Japan
Kyushu University Hospital
RECRUITING

Higashi-Ku, Fukuoka, 812-8582, Japan
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, Japan, 104-0045, Japan
Okayama University Hospital
RECRUITING

Okayama, 700-8558, Japan
Tohoku University Hospital
RECRUITING

Aoba-ku, Sendai, Miyagi, 980-8574, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.